{"title":"Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.","authors":"Salar Saadi Hussain, Zahra Abdulqader Amin","doi":"10.1080/23723556.2026.2692231","DOIUrl":null,"url":null,"abstract":"<p><p>Endometrial cancer (EC) is a heterogeneous gynecological malignancy characterized by diverse genetic and epigenetic alterations. This study investigated genetic mutations associated with EC among Kurdish women using next-generation sequencing (NGS). Seventy histopathologically confirmed EC cases were included, and peripheral blood DNA samples were analyzed. Whole-exome sequencing was performed on nine carefully selected cases based on specific clinical and pathological criteria, including early age of onset and/or family history suggestive of hereditary cancer predisposition, following enzymatic fragmentation, adapter ligation, PCR amplification, and targeted capture using biotinylated probes. The analysis identified five potentially significant variants in five genes: CHEK2, MUTYH, PLA2G2A, POLE, and USF3. The detected alterations included a heterozygous deletion in CHEK2 (p. Tyr113del), a homozygous SNP in MUTYH (p. Arg217His), heterozygous SNPs in PLA2G2A (p. Arg77Gly) and POLE (p. Ser2237Arg), and a heterozygous deletion in USF3 (p. Val576del). These findings highlight important molecular features of EC in Kurdish patients and may support future development of targeted therapeutic strategies. Further validation with larger cohorts is recommended.</p>","PeriodicalId":37292,"journal":{"name":"Molecular and Cellular Oncology","volume":"13 1","pages":"2692231"},"PeriodicalIF":1.9000,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313259/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723556.2026.2692231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Endometrial cancer (EC) is a heterogeneous gynecological malignancy characterized by diverse genetic and epigenetic alterations. This study investigated genetic mutations associated with EC among Kurdish women using next-generation sequencing (NGS). Seventy histopathologically confirmed EC cases were included, and peripheral blood DNA samples were analyzed. Whole-exome sequencing was performed on nine carefully selected cases based on specific clinical and pathological criteria, including early age of onset and/or family history suggestive of hereditary cancer predisposition, following enzymatic fragmentation, adapter ligation, PCR amplification, and targeted capture using biotinylated probes. The analysis identified five potentially significant variants in five genes: CHEK2, MUTYH, PLA2G2A, POLE, and USF3. The detected alterations included a heterozygous deletion in CHEK2 (p. Tyr113del), a homozygous SNP in MUTYH (p. Arg217His), heterozygous SNPs in PLA2G2A (p. Arg77Gly) and POLE (p. Ser2237Arg), and a heterozygous deletion in USF3 (p. Val576del). These findings highlight important molecular features of EC in Kurdish patients and may support future development of targeted therapeutic strategies. Further validation with larger cohorts is recommended.
期刊介绍:
For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.